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Abstract - Cervical cancer incidence and mortality rates in Serbia are among the highest in Europe and data on Human 
papilloma virus (HPV) type distribution are scarce. The aim of this study was to determine the prevalence of HPV types in 
archival specimens of cervical cancer tissues of women in the Serbian population. A total of 45 parafﬁn-embedded tissue 
samples of cervical carcinoma were used in this study. The procedure included deparaffinization of tissue samples, DNA 
extraction, PCR, gel electrophoresis and HPV genotyping by direct sequencing. HPV was detected in 32 samples (71%). 
Genotyping revealed the presence of 6 high-risk HPV types 16, 18, 33, 45, 53 and 58, where HPV type 16 was the most 
prevalent type (73.7%). The results of this study and further studies will provide more detailed information about HPV 
genotype distribution and may contribute to the formulation of national guidelines for the prevention of cervical cancer.
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INTRODUCTION
Cervical cancer is the second most frequent cancer 
in women worldwide in general, as well as among 
women  between  15  and  44  years  of  age.  Current 
estimates indicate that every year ~500 000 women 
are diagnosed with cervical cancer and ~280 000 die 
from the disease (WHO, 2007).
Numerous studies have demonstrated a strong 
and causal association between HPV and cervical 
cancer (Bosch et al., 2008). So far, more than 120 
HPV genotypes have been identiﬁed and according 
to the oncogenic potential they are classiﬁed into 
two groups. High-risk genotypes are associated with 
cervical cancer while low-risk types are associated 
with genital warts. All genotypes can cause an ab-
normal Pap test (Bernard et al., 2010; Clifford et al., 
2006). 
About 10% of women in the general population 
are estimated to harbour cervical HPV infection at 
a given time, and 70.1% of invasive cervical cancers 
in the world are attributed to HPVs 16 or 18. HPV 
DNA can be detected in nearly all invasive cervical 
lesions (Walboomers et al., 1999). Results of previous 
studies revealed that, on average, 93% of cervical tis-
sues contained HPV DNA (range 75-100%) (Bosch 
et al., 1995). In addition, results from an updated me-
ta-analysis showed that the overall HPV prevalence 
in invasive cervical cancer (ICC) was 87%, ranging 
from 86% to 94% by region (Smith et al, 2007).574 M. STAMENKOVIĆ ET AL.
Most  commonly,  HPV  16  and  HPV  18  types 
are  isolated  from  cervical  cancer  worldwide,  but 
there  are  several  oncogenic  types  of  considerable 
importance, i.e. types 33, 45, 31, 58, 52, 35, 59 and 
51 (WHO, 2007). An updated meta-analysis showed 
similar results of HPV type distribution for the Euro-
pean region (Smith et al., 2007).
Therefore, the determination of prevalence and 
HPV genotype distribution is very important for de-
ﬁning and monitoring of HPV infection and cancer 
prevention strategies (Bosch et al., 2008). 
Cervical cancer is the leading cause of cancer 
mortality  among  women  in  Serbia,  where  the  in-
cidence of cervical cancer is among the highest in 
Europe. According to the data of the Cancer Reg-
istry of Serbia, from 1973-1982 the incidence was 
14.7 to 18.2 per 100 000, while in the year 2002 the 
age-standardized  incidence  rate  of  cervical  cancer 
was 27.2 per 100 000. Recent data from 2003-2009 
showed incidence rates from 21.6 to 27.1 per 100 000 
(Kesic et al., 2007; Cancer Registry of Serbia, 2011). 
The data on HPV genotype distribution in cervi-
cal cancer tissues in Serbia are limited. Therefore, the 
aim of this study was to determine the prevalence of 
HPV types in archival specimens of cervical cancer 
tissues of women in our population.
MATERIALS AND METHODS
Tissue samples
A  total  of  45  formalin-ﬁxed  paraffin-embedded 
(FFPE) tissue samples of histologically proven cer-
vical carcinoma diagnosed during 2009-2012 were 
obtained from the archives of the University Clinic 
of Gynecology and Obstetrics “Narodni Front”, Bel-
grade. Sections from each tissue block were haema-
toxylin and eosin (H&E)-stained and assessed by the 
study pathologist to conﬁrm the histological diag-
nosis. Depending on the tissue size, three to ﬁve 5 
mm serial sections were cut from each paraffin tissue 
block and collected in 1.5 ml tubes for DNA extrac-
tion. To avoid cross-contamination of samples, the 
microtome blade was carefully cleaned with xylene 
after each cut. 
HPV DNA amplification and detection
The tissue sections were deparaffinised with xylene 
and 96% ethanol, and DNA extraction was done with 
a QIAamp DNA Mini Kit (QIAGEN Inc., CA, USA), 
according to the manufacturer’s instructions. 
The presence of HPV was determined by PCR 
method using MY09/MY11 primers for the detection 
of the L1 gene and GP1/GP2 primers for the detec-
tion of the E1 gene HPV DNA (Gravitt et al., 2000; 
Azzimonti et al., 1999). PCRs were performed in a 25 
μL volume reaction mix containing Qiagen Taq PCR 
Master Mix-250U (QIAGEN Inc., CA, USA), 1 μmol 
of each primer and 5 μl of extracted DNA. 
The ampliﬁcation for the L1 gene was performed 
with the following cycling protocol: initial denatura-
tion at 95°C for 5 min, followed by 40 cycles of 30 s at 
94°C, 30 s at 58°C, 1 min at 72°C and a ﬁnal elonga-
tion of 20 min at 72°C (Gravitt et al., 2000). The PCR 
protocol for E1 gene included: initial denaturation 
at 85°C for 5 min, followed by 40 cycles of 1min at 
94°C, 1min at 50°C, 90 s at 72°C and a ﬁnal elonga-
tion of 10 min at 72°C (Azzimonti et al., 1999). A 
speciﬁc 450bp band for the L1 gene and 450bp for the 
E1 gene were detected by agarose gel electrophoresis 
with ethidium bromide staining.
HPV genotyping
The determination of HPV genotypes was performed 
by  direct  DNA  sequencing  method.  HPV-positive 
samples were puriﬁed using the QIAGEN MinElute 
PCR Puriﬁcation Kit (QIAGEN Inc., CA, USA). Se-
quencing was performed using a Big Dye Termina-
tor Cycle Sequencing Kit (PE Applied Biosystems, 
CA, USA) with PCR primers as sequencing primers. 
Analysis of the HPV DNA sequences was performed 
by ABI Prism 310 Genetic Analyser and Sequence 
Analysis 5.1 software. The obtained sequences were 
compared with already known sequences using the 
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in the GenBank database. The nucleotide sequence 
was assigned to an HPV type if it corresponded in 
more than 95% in 350-400bp with a known HPV gen-
otype (Remmerbach et al., 2004; Lee et al., 2007).
RESULTS
The mean age of women with invasive cervical car-
cinoma included in the study was 49.31 years (range 
34-75). Out of 45 cervical carcinoma tissue samples, 
37 (82.2%) were squamous cell carcinomas (SCC) 
and 8 (17. 8%) adenocarcinomas (AC).
The presence of HPV DNA was detected in 32 
tissue samples (71%) using the PCR method (Fig. 
1). 
HPV genotype was determined in 19 of 32 posi-
tive samples. Genotyping revealed the presence of 6 
high-risk HPV types: 16, 18, 33, 45, 53 and 58. The 
most prevalent type was HPV 16, found in 14 cases 
(73.84%). Other types (type 18, 33, 45, 58) were de-
tected in one case each (5.26%). In one tissue sample 
(5.26%), two HPV types, 16 and 53, were identiﬁed 
(Table 1).  
DISCUSSION
Genital HPV infection is a highly prevalent, sexu-
ally transmitted infection responsible for signiﬁcant 
morbidity  and  mortality.  Numerous  studies  have 
demonstrated  a  strong  and  causal  association  be-
tween HPV and cervical cancer (Bosch et al., 2008). 
The results of updated meta-analysis showed that the 
overall HPV prevalence in invasive cervical cancer 
was 87%, ranging from 86% to 94% by region (Smith 
et al., 2007).
The overall prevalence of HPV DNA in FFPE 
tissue samples of invasive cervical carcinoma in our 
study population was 71%. This ﬁnding is similar to 
those reported in studies from other countries show-
ing the prevalence of HPV in cervical carcinoma. 
Archival  FFPE  tissues  are  an  important  resource 
Table 1. HPV genotype distribution in cervical carcinoma.
HPV genotype Number of samples % samples (binomial 95% CI)
16 14 73.84 (48.8  to  90.8)
18 1 5.26 (0.01 to 2.6)
33 1 5.26 (0.01 to 2.6)
45 1 5.26 (0.01 to 2.6)
58 1 5.26 (0.01 to 2.6)
16+53 1 5.26 (0.01 to 2.6)
Figure 1. HPV detection by PCR (N – negative control; P – posi-
tive control; 1 – sample).576 M. STAMENKOVIĆ ET AL.
for studies on the pathogenesis of cervical carcino-
ma and they have been used by many authors from 
different  countries  to  investigate  HPV  prevalence. 
However, the sensitivity of PCR in FFPE tissue sam-
ples is strongly related to the size of the PCR product. 
Baay et al. (1996) reported that the efficacy of GP5/6, 
CPI/IIG and MY09/11 general primer pairs for de-
tection of HPV DNA in FFPE carcinomas correlated 
with the length of the produced amplicons. The HPV 
positivity with GP5/6 primers (amplicon 155bp) was 
61%, with CPI/IIG primers (amplicon 188bp) 57% 
and with MY09/11 primers (amplicon 450bp) 47%. 
It has been suggested that formaldehyde ﬁxation can 
modify viral DNA and the ampliﬁcation of a PCR 
product longer than 200bp is inhibited (Baay et al., 
1996; Karlsen et al., 1994). The HPV positivity in 
FFPE tissue samples using MY09/11 and GP1/GP2 
primers (amplicons 450bp) in this study was higher. 
More than 120 types of HPV have been discov-
ered and are generally classiﬁed as high-risk or low-
risk types on the basis of their oncogenicity. Among 
the high-risk types, HPV 16 and 18 account for ap-
proximately 70% of all cases of cervical cancer. Other 
high-risk types such as 33, 45, 31, 58, 52, 35, 59 and 
51 are detected with less frequency (WHO, 2007). 
Similar results of HPV type distribution in cervical 
carcinoma are demonstrated in the European region 
(Smith et al., 2007).
In our study, 6 high-risk HPV types were identi-
ﬁed by direct DNA sequencing method in cervical 
carcinoma tissues (16, 18, 33, 45, 53 and 58). HPV 
type 16 was the most prevalent type and was found 
as a single infection in 14 cases (73.84%). The over-
all prevalence of HPV types 16 and 18 was 79.1%. 
This result is similar to the rates of HPV types 16 
and 18 detected in FFPE tissues in Italy (67.8% and 
10.7%, respectively) and in Turkey (64.7% and 9.9%, 
respectively), although the prevalence of HPV type 
18 in these countries was higher (Rossi et al., 2012; 
Usubütün et al., 2009). This is not surprising, as pre-
vious studies have shown that HPV type 16 is the 
predominant genotype in SCC, and HPV type 18 in 
adenocarcinoma, so our results were compliant with 
histological type distribution in our samples (82.20% 
SCC and 17.80% AC). In addition, these variations in 
HPV types 16 and 18 prevalence may be attributable 
to geographic differences, to the different numbers of 
cases included in the study, or to the use of different 
techniques for HPV detection, including the use of 
different primer pairs.
The presence of multiple HPV genotypes is less 
prevalent in cervical carcinoma (Molijn et al., 2005). 
In our study, in one cervical carcinoma tissue, two 
HPV types, 16 and 53, were identiﬁed.
Cervical cancer prevention programs in devel-
oped countries include HPV testing and vaccination 
of young women against HPV types 16 and 18. Nu-
merous studies showed that the vaccines are highly 
effective in preventing the development of cervical 
precancerous lesions associated with HPV type 16 or 
18 (Castellsague et al., 2009; Lu et al., 2011).
Therefore, the results of this study indicate that 
HPV types 16 and 18 are important risk factors for 
cervical cancer in Serbia and that at least 79% of 
cervical cancer cases in this country are potentially 
preventable by currently available prophylactic HPV 
vaccines. Furthermore, the results of this study and 
further studies will provide more detailed informa-
tion  about  HPV  genotype  distribution  in  cervical 
cancer tissues of women in our population and may 
contribute in the formulation of national guidelines 
for the prevention of cervical cancer.
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